You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
News and reporting on breast cancer.
The US DOJ alleged that the company conspired to "artificially delay" ordering its MammaPrint test in order to circumvent Medicare's 14-day rule.
The company recently presented results from its Aurora assay for multi-cancer screening and plans to launch a $100 test for the US and Chinese markets.
In a proof-of-concept study, the group has demonstrated its platform could detect a biomarker of breast tumor metastasis and other disease biomarkers.
At the American Society of Clinical Oncology's virtual meeting, investigators presented two new studies of BluePrint classification patterns.
The decision comes after Myriad requested expanded coverage for women with breast cancer seeking information about extending endocrine therapy.
New data shows that the test could eventually be useful in helping younger women avoid chemotherapy in the neoadjuvant setting.
In the near term, the firm will launch a laboratory-developed, late-stage lung cancer assay out of its lab in Palo Alto.
The deal includes integrating an online ordering process for Ambry's genetic tests into Volpara's Aspen Breast software for medical practice management.
Celcuity's companion diagnostic platform CELsignia identifies cellular signals corresponding to drug response using a patient's living tumor cells.
The firm has collected important health economic evidence for its clinical lung cancer assay and is building evidence for other products in additional cancer types.